Patritumab deruxtecan

Patritumab deruxtecan (HER3-DXd) (0.04-10 µg/mL; 5 days) decreases viability and induces calreticulin relocation in HER3-overexpressing U2OS-CALR-GFP cells, but not in parental HER3-negative U2OS-CALR-GFP cells^[3].
Patritumab deruxtecan (0.16 µg/mL; 5 days) induces hallmarks of immunogenic cell death, including calreticulin surface exposure, extracellular ATP release, and HMGB1 release, in HER3-overexpressing U2OS cells, but not in parental HER3-negative U2OS cells^[3].
Patritumab deruxtecan (0.16 µg/mL; 5 days) induces bystander antitumor effects, reducing viability of HER3-negative U2OS cells when cocultured with HER3-overexpressing U2OS cells^[3].
Patritumab deruxtecan (0.16 µg/mL; 5 days) releases its cytotoxic payload DXd into cell culture supernatants when applied to HER3-overexpressing U2OS cells, either alone or in coculture with HER3-negative U2OS cells^[3].
Patritumab deruxtecan (0.1-100 nM; 1 h) binds specifically and with comparable affinity to MDA-MB-231 cells expressing HER3 wild type or clinically reported HER3^G12C mutations, regardless of HER2 overexpression, with no binding to HER3-negative MDA-MB-231 cells^[4].
Patritumab deruxtecan (10 nM; 6 days) significantly inhibits the growth of MDA-MB-231 cells expressing HER3 wild type or most clinically reported HER3 mutations, with activity observed regardless of HER2 overexpression, and no activity against HER3-negative MDA-MB-231 cells^[4].
Patritumab deruxtecan (0.1-10 nM; up to 12 h) undergoes time- and concentration-dependent lysosomal trafficking in MDA-MB-231 cells expressing HER3 wild type or clinically reported HER3^G12C mutations, at comparable levels regardless of HER2 overexpression, with minimal trafficking in HER3-negative MDA-MB-231 cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.